The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! The stock increased 2.96% or $0.28 during the last trading session, hitting $9.73. About 371,323 shares traded hands. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 55.17% since February 26, 2016 and is uptrending. It has outperformed by 44.75% the S&P500.
The move comes after 5 months positive chart setup for the $340.10 million company. It was reported on Oct, 1 by Barchart.com. We have $21.11 PT which if reached, will make NASDAQ:KPTI worth $397.92 million more.
Analysts await Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report earnings on November, 14. They expect $-0.77 earnings per share, up 9.41% or $0.08 from last year’s $-0.85 per share. After $-0.84 actual earnings per share reported by Karyopharm Therapeutics Inc for the previous quarter, Wall Street now forecasts -8.33% EPS growth.
Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage
Out of 11 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 10 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 91% are positive. Karyopharm Therapeutics Inc. has been the topic of 18 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was initiated by JP Morgan with “Overweight” on Wednesday, September 2. JP Morgan maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Monday, March 14 with “Overweight” rating. On Wednesday, January 6 the stock rating was downgraded by Jefferies to “Hold”. MLV maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Wednesday, August 12 with “Buy” rating. The rating was upgraded by Jefferies to “Buy” on Tuesday, August 30. Jefferies initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) rating on Wednesday, September 9. Jefferies has “Buy” rating and $23 price target. Leerink Swann maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, August 11 with “Outperform” rating. H.C. Wainwright initiated Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Thursday, August 18 with “Buy” rating. Bank of America downgraded Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, March 15 to “Underperform” rating. JMP Securities maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Wednesday, March 9 with “Market Outperform” rating.
According to Zacks Investment Research, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 1.01, from 0.53 in 2016Q1. The ratio is positive, as 11 funds sold all Karyopharm Therapeutics Inc shares owned while 15 reduced positions. 10 funds bought stakes while 30 increased positions. They now own 19.84 million shares or 5.28% less from 20.95 million shares in 2016Q1.
Tcw Gru last reported 0% of its portfolio in the stock. Goldman Sachs Grp Inc reported 41,264 shares or 0% of all its holdings. Proshare Advsr Lc has 0% invested in the company for 29,655 shares. Blackrock Grp holds 6,454 shares or 0% of its portfolio. Wellington Management Limited Liability Partnership last reported 0% of its portfolio in the stock. Blackrock Fund holds 1.07 million shares or 0% of its portfolio. Moreover, Stoneridge Prtn Ltd Llc has 0.03% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 32,465 shares. Teacher Retirement System Of Texas owns 3,006 shares or 0% of their US portfolio. Northern Trust reported 257,473 shares or 0% of all its holdings. Blackrock, a New York-based fund reported 6,497 shares. Schwab Charles Invest Mgmt last reported 0% of its portfolio in the stock. Morgan Stanley owns 5,166 shares or 0% of their US portfolio. Highbridge Management Lc has 29,907 shares for 0% of their US portfolio. Franklin Res reported 3.28 million shares or 0.01% of all its holdings. Ellington Management Ltd Liability last reported 16,200 shares in the company.
Insider Transactions: Since May 10, 2016, the stock had 0 buys, and 10 insider sales for $3.86 million net activity. Chione Ltd had sold 45,541 shares worth $419,284 on Wednesday, June 8.
Another recent and important Karyopharm Therapeutics Inc (NASDAQ:KPTI) news was published by Streetinsider.com which published an article titled: “Karyopharm Therapeutics (KPTI) Announces Publication of Strong Preclinical …” on September 29, 2016.
KPTI Company Profile
Karyopharm Therapeutics Inc., incorporated on December 22, 2008, is a clinical-stage pharmaceutical company. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The Company’s segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases. The Firm has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company’s lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. The Firm is also engaged in the clinical development of selinexor in various solid tumor indications. The Firm has initiated various later-phase clinical trials to evaluate selinexor in hematological cancers and solid tumors. The Firm has also initiated a double-blinded, placebo-controlled, randomized Phase II/III study of single-agent selinexor in liposarcoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.